Literature DB >> 12378517

Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma.

Rajshri N Shah1, Sunil Badve, Kashireddy Papreddy, Susanne Schindler, William B Laskin, Anjana V Yeldandi.   

Abstract

Mucinous bronchioloalveolar carcinomas (BACs) can closely mimic metastatic adenocarcinoma to the lung both clinically and morphologically. Several studies have demonstrated that the differential expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is a valuable diagnostic tool in differentiating primary pulmonary adenocarcinomas (PPAs) (usually CK7 positive/CK20 negative) from metastatic colonic adenocarcinoma (usually CK7 negative/CK20 positive). The present study is designed to correlate the histologic subtypes of PPA with expression of 7 and 20. A total of 113 cases of bonafide PPA were selected and classified according to the 1999 World Health Organization criteria as adenocarcinoma, NOS (n = 80), nonmucinous BAC (n = 14), and mucinous BAC (n = 19). Representive sections of all the tumors were immunohistochemically analyzed for CK7 and CK20 expression. To evaluate the diagnostic utility of CK7 and CK20 expression, 6 cases of colonic adenocarcinoma metastatic to the lung were tested with the same antibodies and compared with mucinous BAC. Results were expressed in a semiquantitative fashion based on the percentage of positive tumor cells: <10%, focal; 10% to 25%, 1+; 26% to 75%, 2+; > or =76%, 3+. All 113 PPAs exhibited strong, diffuse CK7 expression. With respect to CK20 expression, 17 of the 19 cases (89.4%) of mucinous BAC showed moderate to strong expression of this protein, whereas only 10 cases of conventional adenocarcinomas and 4 cases of nonmucinous BAC exhibited expression. All 6 examples of metastatic colonic adenocarcinomas were negative for CK7 and strongly positive for CK20. In summary, mucinous BAC is distinct from other PPAs by virtue of its CK20 expression. Although the CK7/CK20 immunoprofile is a valuable diagnostic marker for differentiating primary lung adenocarcinoma from metastatic colonic adenocarcinoma, caution should be exercised when dealing with mucinous BAC. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378517     DOI: 10.1053/hupa.2002.126876

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Mucinous carcinoma identified as lung metastasis from an early rectal cancer with submucosal invasion by immunohistochemical detection of villin.

Authors:  Naoyuki Yoshino; Hirotoshi Kubokura; Shigeo Yamauchi; Yoshiharu Ohaki; Kiyoshi Koizumi; Kazuo Shimizu
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-08

3.  Bronchioloalveolar differentiation in lung adenocarcinomas.

Authors:  Nevena Dukić; Božana Babić; Zivka Eri; Dragana Zec; Aleksandra Lovrenski; Violeta Kolarov
Journal:  Bosn J Basic Med Sci       Date:  2011-11       Impact factor: 3.363

Review 4.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

5.  Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival.

Authors:  Abidin Geles; Ulrike Gruber-Moesenbacher; Franz Quehenberger; Claudia Manzl; Mohamed Al Effah; Elisabeth Grygar; Freyja Juettner-Smolle; Helmut H Popper
Journal:  Virchows Arch       Date:  2015-10-08       Impact factor: 4.064

6.  CD208/dendritic cell-lysosomal associated membrane protein is a marker of normal and transformed type II pneumocytes.

Authors:  Bruno Salaun; Blandine de Saint-Vis; Nathalie Pacheco; Yves Pacheco; Arnaud Riesler; Sylvie Isaac; Caroline Leroux; Valérie Clair-Moninot; Jean-Jacques Pin; Janice Griffith; Isabelle Treilleux; Sophie Goddard; Jean Davoust; Monique Kleijmeer; Serge Lebecque
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

7.  Lung adenocarcinoma mimicking pulmonary fibrosis-a case report.

Authors:  Bakir Mehić; Lina Duranović Rayan; Nurija Bilalović; Danina Dohranović Tafro; Ilijaz Pilav
Journal:  BMC Cancer       Date:  2016-09-13       Impact factor: 4.430

Review 8.  Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression.

Authors:  Kentaro Inamura
Journal:  Int J Mol Sci       Date:  2018-04-23       Impact factor: 5.923

9.  Long-term survival after repeated resection for lung metastasis originating from pancreatic cancer: a case report.

Authors:  Yasunori Uesato; Koichi Tamashiro; Mitsuhisa Takatsuki
Journal:  Surg Case Rep       Date:  2020-04-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.